Dr. Roberto Salgado is board certified in Anatomical Pathology since 2006 and works as an Anatomic Pathologist in Antwerp, Belgium. Currently, he's co-chairing with Sherene Loi, Peter Mac Callum Cancer Center, Melbourne, Australia, and Carsten Denkert, University of Marburg, Germany, an International Consortium of Pathologists, namely the "International Immuno-Oncology Biomarkers Working Group" (www.tilsinbreastcancer.org) that develops guidelines for the assessment of Immuno-Oncological Biomarkers in mostly breast cancer. This Working Group is a pathologist-driven group, with >900 pathologists on board, from 58 countries, and aims to develop guidelines and tools to help pathologists implement TILs in daily and clinical trial practices, including AI-TIL assays in clinical trials, publishing >15 manuscripts over the past 10 years.

 

Dr. Roberto Salgado also works with the Tracer-X Consortium at the Francis Crick Institute, London, UK, led by Charles Swanton, helping to decipher the immunological evolutionary pressures in lung cancer (Home ).

 

His strategic views on Oncology have been published in major international high impact factor journals such as Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery, and Lancet Oncology. Research work has been published in Nature, The Lancet Oncology, The Lancet, Journal of Clinical Oncology, Nature Medicine.

 

Finally, he's member of the WHO Editorial Board of the WHO Classification of Breast Tumours.

Dr Roberto Salgado has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Merck, Daiichi Sankyo, Exact Sciences, Puma Biotechnology, Roche: all for research support or for educational activities.